Page last updated: 2024-08-22

camptothecin and azomycin

camptothecin has been researched along with azomycin in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P	1
Ahluwalia, D; Ammons, WS; Baker, AF; Cranmer, LD; Curd, JG; Duan, JX; Ferraro, D; Hart, CP; Liu, Q; Matteucci, MD; Sun, JD; Wang, J; Wang, Y	1

Other Studies

2 other study(ies) available for camptothecin and azomycin

Article	Year
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine. Bioorganic & medicinal chemistry, 2012, Nov-15, Volume: 20, Issue:22 Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship	2012
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Evaluation, Preclinical; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Mice; Mice, SCID; Nitroimidazoles; Pemetrexed; Phosphoramide Mustards; Prodrugs; Taxoids; Xenograft Model Antitumor Assays	2012

Article

Year

Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.

Bioorganic & medicinal chemistry, 2012, Nov-15, Volume: 20, Issue:22

Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship

2012

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:6

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Evaluation, Preclinical; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Mice; Mice, SCID; Nitroimidazoles; Pemetrexed; Phosphoramide Mustards; Prodrugs; Taxoids; Xenograft Model Antitumor Assays

2012